公开(公告)号：US11634773B2

公开(公告)日：2023-04-25

申请号：US16628067

申请日：2018-07-13

Applicant: THE FRANCIS CRICK INSTITUTE LIMITED ,  UNIVERSITY COLLEGE LONDON ,  CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Charles Swanton ,  Nicholas McGranahan ,  Rachel Rosenthal

IPC: C12Q1/6881 ,  C12Q1/6869 ,  A61K39/00 ,  C12Q1/6886 ,  C07K14/74 ,  C07K16/28

Abstract: The present invention relates to a method for determining whether an HLA allele is lost in a tumour in a subject, wherein said method comprises the step of determining the specific copy number of said HLA allele in said tumour. The invention also relates to a method for treating cancer in a subject, comprising targeting a neoantigen which is predicted to be presented by an HLA molecule encoded by an HLA allele which has been determined not to have been lost in a tumour in said subject.

公开(公告)号：US11098121B2

公开(公告)日：2021-08-24

申请号：US15758165

申请日：2016-09-12

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Nicholas McGranahan ,  Rachel Rosenthal ,  Charles Swanton ,  Karl Peggs ,  Sergio Quezada

IPC: A61K39/395 ,  G16B30/00 ,  C07K16/28 ,  G16B40/00 ,  G01N33/574

Abstract: The present invention relates to methods for identifying a subject with cancer who is suitable for treatment with an immune checkpoint intervention, and to methods of treatment of such subjects. The invention further relates to a method for predicting or determining the prognosis of a subject with cancer.

公开(公告)号：US20210147934A1

公开(公告)日：2021-05-20

申请号：US16628067

申请日：2018-07-13

Applicant: THE FRANCIS CRICK INSTITUTE LIMITED ,  UNIVERSITY COLLEGE LONDON ,  CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Charles Swanton ,  Nicholas McGranahan ,  Rachel Rosenthal

IPC: C12Q1/6881 ,  C12Q1/6886 ,  A61K39/00 ,  C12Q1/6869

Abstract: The present invention relates to a method for determining whether an HLA allele is lost in a tumour in a subject, wherein said method comprises the step of determining the specific copy number of said HLA allele in said tumour. The invention also relates to a method for treating cancer in a subject, comprising targeting a neoantigen which is predicted to be presented by an HLA molecule encoded by an HLA allele which has been determined not to have been lost in a tumour in said subject.

公开(公告)号：US20180251553A1

公开(公告)日：2018-09-06

申请号：US15758165

申请日：2016-09-12

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Nicholas McGranahan ,  Rachel Rosenthal ,  Charles Swanton ,  Karl Peggs ,  Sergio Quezada

IPC: C07K16/28 ,  G06F19/22 ,  G06F19/24 ,  G01N33/574

CPC classification number: C07K16/2818 ,  C07K2317/24 ,  C07K2317/76 ,  G01N33/574 ,  G01N33/57411 ,  G16B30/00 ,  G16B40/00

Abstract: The present invention relates to methods for identifying a subject with cancer who is suitable for treatment with an immune checkpoint intervention, and to methods of treatment of such subjects. The invention further relates to a method for predicting or determining the prognosis of a subject with cancer.

公开(公告)号：US20200000904A1

公开(公告)日：2020-01-02

申请号：US16565350

申请日：2019-09-09

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Nicholas McGranahan ,  Rachel Rosenthal ,  Charles Swanton ,  Karl Peggs ,  Sergio Quezada

IPC: A61K39/00 ,  C12Q1/6886 ,  C12N5/0783 ,  G01N33/50 ,  G01N33/574

Abstract: The present invention relates to a method for identifying a truncal neo-antigen in a tumour from a subject which comprises the steps of: i) determining mutations present in a sample isolated from the tumour; and ii) identifying a truncal mutation which is a mutation present in essentially all tumour cells; and iii) identifying a truncal neo-antigen, which is an antigen encoded by a sequence which comprises the truncal mutation.

公开(公告)号：US20200000903A1

公开(公告)日：2020-01-02

申请号：US16565342

申请日：2019-09-09

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Nicholas McGranahan ,  Rachel Rosenthal ,  Charles Swanton ,  Karl Peggs ,  Sergio Quezada

IPC: A61K39/00 ,  C12Q1/6886 ,  C12N5/0783 ,  G01N33/50 ,  G01N33/574

Abstract: The present invention relates to a method for identifying a truncal neo-antigen in a tumour from a subject which comprises the steps of: i) determining mutations present in a sample isolated from the tumour; and ii) identifying a truncal mutation which is a mutation present in essentially all tumour cells; and iii) identifying a truncal neo-antigen, which is an antigen encoded by a sequence which comprises the truncal mutation.

公开(公告)号：US20180064793A1

公开(公告)日：2018-03-08

申请号：US15569334

申请日：2016-04-27

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Nicholas Mcgranahan ,  Rachel Rosenthal ,  Charles Swanton ,  Karl Peggs ,  Sergio Quezada

IPC: A61K39/00 ,  C12Q1/68 ,  C12N5/0783 ,  G01N33/574 ,  G01N33/50

CPC classification number: A61K39/0011 ,  C12N5/0636 ,  C12N2501/505 ,  C12N2502/99 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N33/505 ,  G01N33/57423 ,  G01N33/5743

Abstract: The present invention relates to a method for identifying a truncal neo-antigen in a tumour from a subject which comprises the steps of: i) determining mutations present in a sample isolated from the tumour; and ii) identifying a truncal mutation which is a mutation present in essentially all tumour cells; and iii) identifying a truncal neo-antigen, which is an antigen encoded by a sequence which comprises the truncal mutation.